ReviewInflammatory bowel diseases2020
Toward Molecular Imaging of Intestinal Pathology.
Review in Inflammatory bowel diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 21 citations in OpenAlex.
- Role of MRI radiomics in deep learning-based prediction of intestinal diseases.International journal of colorectal disease · 2026Review
- Four-class classification of tumor-induced colorectal obstruction histopathology: A ResNet-mamba-mased study on cellular interaction pattern recognition.Scientific reports · 2025Article
- The role of molecular imaging in detecting fibrosis in Crohn's disease.Annals of medicine · 2024Review
- Complicated Inguinal Hernia Incidentally Detected on a Radiolabelled Autologous White Blood Cell Scan.Nuclear medicine and molecular imaging · 2024Article
- Radiology of fibrosis part II: abdominal organs.Journal of translational medicine · 2024Review
- Detection of IL12/23p40 via PET Visualizes Inflammatory Bowel Disease.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- Molecular Imaging of Inflammatory Disease.Biomedicines · 2021Review
- Defining the Path Forward for Biomarkers to Address Unmet Needs in Inflammatory Bowel Diseases.Inflammatory bowel diseases · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Inflammatory bowel disease (IBD) is defined by a chronic relapsing and remitting inflammation of the gastrointestinal tract, with intestinal fibrosis being a major complication. The etiology of IBD remains unknown, but it is thought to arise from a dysregulated and excessive immune response to gut luminal microbes triggered by genetic and environmental factors. To date, IBD has no cure, and treatments are currently directed at relieving symptoms and treating inflammation. The current diagnostic of IBD relies on endoscopy, which is invasive and does not provide information on the presence of extraluminal complications and molecular aspect of the disease. Cross-sectional imaging modalities such as computed tomography enterography (CTE), magnetic resonance enterography (MRE), positron emission tomography (PET), single photon emission computed tomography (SPECT), and hybrid modalities have demonstrated high accuracy for the diagnosis of IBD and can provide both functional and morphological information when combined with the use of molecular imaging probes. This review presents the state-of-the-art imaging techniques and molecular imaging approaches in the field of IBD and points out future directions that could help improve our understanding of IBD pathological processes, along with the development of efficient treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.